bortezomib has been researched along with mofezolac* in 1 studies
1 other study(ies) available for bortezomib and mofezolac
| Article | Year |
|---|---|
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the most potent and selective reversible COX-1 inhibitor [COX-1 IC Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Multiple Myeloma; Platelet Aggregation Inhibitors; Protein Binding; Structure-Activity Relationship | 2019 |